Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In general good health~* Female participants have a negative pregnancy test just prior to vaccination on Day 1~Exclusion Criteria:~* History of Hepatitis B Infection or vaccination~* Known or suspected hypersensitivity to any component of Recombivax HB™ vaccine (e.g., aluminum, yeast)~* Administration of hepatitis B immune globulin, serum immune globulin, or any other blood-derived product within 3 months prior to vaccination on Day 1~* Receipt of an inactivated virus vaccine within 14 days or a live virus vaccine within 30 days prior to vaccination on Day 1~* Participation on prior study using an investigational drug or vaccine in prior 3 months~* Known or suspected impairment of immunologic function or recent use of immunomodulatory medications, excluding topical or inhaled steroids~* Pregnant or nursing women or women planning to become pregnant within the study period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- V232 Modified Process Hepatitis B Vaccine: Lot A (Type: EXPERIMENTAL): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
- V232 Modified Process Hepatitis B Vaccine: Lot B (Type: EXPERIMENTAL): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
- V232 Modified Process Hepatitis B Vaccine: Lot C (Type: EXPERIMENTAL): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
- V232 Current Process Hepatitis B Vaccine (Type: ACTIVE_COMPARATOR): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).